Healthy Returns: A key step forward for Novo Nordisk's GLP-1 pill

1. Novo Nordisk's oral semaglutide approved for cardiovascular risk reduction. 2. Approval could enhance GLP-1 market demand for diabetes and obesity treatments. 3. FDA may approve oral semaglutide for obesity by year-end, creating competitive pressures. 4. Novo Nordisk engaged in pricing discussions with Trump administration for drug access. 5. Company ramping up production in NC to meet potential increased demand.